Patent ID: 6303607
Filing Date: 2001-10-16
Classification: A61K,A61P,Y10S

Abstract:
A method for treating a human patient suffering from variant or exercise-induced angina by administering a sustained release pharmaceutical dosage form including at least 50% by weight ranolazine and an admixture of at least one pH-dependent binder and at least one pH-independent binder wherein the pharmaceutical dosage form is administered in no more than two tablets per dose to the human patient to maintain ranolazine plasma levels in the human patient of from about 550 to about 7500 ng base/mL for at least 24 hours wherein the dose is administered at a frequency selected from the group consisting of once, twice or three times over 24 hours and wherein the peak to trough plasma ranolazine level does not exceed 3:1 over a 24 hour period.